Hormone replacement therapy and risk of venous thromboembolism

Miller J, Chan BK, Nelson H
Record ID 32003001088
Authors' objectives:

To assess the risk of venous thromboembolism with the use of postmenopausal hormone replacement therapy (HRT) by literature review and meta-analysis.

Authors' results and conclusions: We used Bayesian meta-analysis. Current HRT use was associated with an increased risk of venous thromboembolism (relative risk [RR], 2.14; CI, 1.64-2.81). The absolute rate increase was 1.5 venous thromboembolic events per 10,000 women in one year. Five case-control studies reported highest risk within the first year of use (odds ratios [OR], 2.9-6.7). Data from 5 randomized controlled trials of selective estrogen receptor modulators (SERMs) were not included in the meta-analysis. The 2 largest trials reported a similar increased risk of venous thromboembolism.
Authors' recommendations: Postmenopausal HRT is associated with an increased risk of venous thromboembolism, and this risk may be highest in the first year of use. SERMs are associated with a similar increase in risk.
Authors' methods: Systematic review
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Postmenopause
  • Thromboembolism
  • Venous Thrombosis
  • Women
  • Hormone Replacement Therapy
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.